| scholarly article | Q13442814 |
| P50 | author | Lela Buckingham | Q92187292 |
| P2093 | author name string | Mark Maienschein-Cline | |
| Lydia Usha | |||
| Melody Cobleigh | |||
| Rachel Mitchell | |||
| Jacob Rotmensch | |||
| Stefan Green | |||
| Kelly Burgess | |||
| Vincent Hong Hu | |||
| P2860 | cites work | Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? | Q52586080 |
| Role for the Werner syndrome protein in the promotion of tumor cell growth. | Q53541570 | ||
| Population-based study of risk of breast cancer in carriers of BRCA2 mutation | Q57250754 | ||
| Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program | Q57903119 | ||
| A common SNP in the UNG gene decreases ovarian cancer risk in BRCA2 mutation carriers | Q64040629 | ||
| BRCA1/2 testing: uptake, phenocopies, and strategies to improve detection rates in initially negative families | Q84947430 | ||
| Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance | Q91972558 | ||
| Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers | Q92036319 | ||
| DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers | Q21144874 | ||
| PALB2 is an integral component of the BRCA complex required for homologous recombination repair | Q24316113 | ||
| Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | Q24531993 | ||
| The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study | Q27644636 | ||
| The Werner syndrome protein at the crossroads of DNA repair and apoptosis | Q28279631 | ||
| Characterization of BRCA1 and BRCA2 mutations in a large United States sample | Q28383993 | ||
| ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data | Q29547161 | ||
| Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium | Q29619206 | ||
| The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews | Q29619407 | ||
| MOSAIK: a hash-based algorithm for accurate next-generation sequencing short-read mapping | Q31153287 | ||
| Detection of BRCA1 and BRCA2 Ashkenazi Jewish founder mutations in formalin-fixed paraffin-embedded tissues using conventional PCR and heteroduplex/amplicon size differences | Q33555632 | ||
| Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers | Q33614244 | ||
| Prepubertal start of father's smoking and increased body fat in his sons: further characterisation of paternal transgenerational responses | Q33856570 | ||
| The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations | Q33946674 | ||
| SGO White Paper on ovarian cancer: etiology, screening and surveillance | Q34622294 | ||
| Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry | Q35609710 | ||
| Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. | Q35643852 | ||
| Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies | Q36281144 | ||
| Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
| Chimerism and tetragametic chimerism in humans: implications in autoimmunity, allorecognition and tolerance | Q36960980 | ||
| Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening | Q37004478 | ||
| Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation | Q37081117 | ||
| Toward better understanding of artifacts in variant calling from high-coverage samples | Q38224122 | ||
| Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer. | Q38966664 | ||
| Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists | Q39043523 | ||
| NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis. | Q39152206 | ||
| Phenocopies in breast cancer 1 (BRCA1) families: implications for genetic counselling | Q43232347 | ||
| BRCA phenocopies or ascertainment bias? | Q43232466 | ||
| Do women remain at risk even if they do not inherit a familial BRCA1/2 mutation? | Q44250031 | ||
| Functional germline variants as potential co-oncogenes | Q47159094 | ||
| Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes | Q47601932 | ||
| Points to consider for sharing variant-level information from clinical genetic testing with ClinVar. | Q49726725 | ||
| DNA methylation in epigenetic inheritance of metabolic diseases through the male germ line. | Q50083143 | ||
| P304 | page(s) | 21 | |
| P577 | publication date | 2019-07-16 | |
| P1433 | published in | Hereditary Cancer in Clinical Practice | Q1843481 |
| P1476 | title | Somatic variants of potential clinical significance in the tumors of BRCA phenocopies | |
| P478 | volume | 17 |
Search more.